Skye Bioscience Reports Promising Phase 2a Obesity Data

An update from Skye Bioscience ( (SKYE) ) is now available.

On February 2, 2026, Skye Bioscience reported interim 52‑week data from the combination arm of its Phase 2a CBeyond extension study in obesity, showing that patients receiving nimacimab plus semaglutide achieved a mean weight loss of 22.3% with no plateau observed, versus 19.7% with semaglutide plus placebo, and that the combination maintained a favorable safety and tolerability profile with no serious adverse events or adverse events of special interest. The company also highlighted that, during a 13‑week off‑therapy period, patients previously treated with the nimacimab–semaglutide combination regained only 17.8% of their lost weight compared with 37.3% for semaglutide alone, suggesting a durability advantage that could strengthen Skye’s competitive positioning in the crowded obesity market as it advances nimacimab toward larger Phase 2b studies and continues to manage its cash runway, which it expects to support operations and key clinical milestones into the fourth quarter of 2026.

The most recent analyst rating on (SKYE) stock is a Hold with a $0.94 price target. To see the full list of analyst forecasts on Skye Bioscience stock, see the SKYE Stock Forecast page.

Spark’s Take on SKYE Stock

According to Spark, TipRanks’ AI Analyst, SKYE is a Neutral.

The score is held down primarily by weak financial performance (no revenue, widening losses, and persistent cash burn) and bearish technicals (below key moving averages with negative MACD). These are partially offset by a constructive earnings-call backdrop (cash runway into 2027 and encouraging Phase 2a combination data) and a positive delivery-technology partnership, while valuation inputs provide limited support due to negative earnings and no dividend yield.

To see Spark’s full report on SKYE stock, click here.

More about Skye Bioscience

Skye Bioscience is a clinical-stage biotechnology company focused on metabolic health, developing next-generation molecules that modulate G‑protein coupled receptors. Its lead asset, nimacimab, is a peripherally acting CB1-inhibiting monoclonal antibody being developed as a first-in-class, non-incretin treatment for obesity, both as monotherapy and in combination with GLP‑1 receptor agonists such as semaglutide (Wegovy).

Average Trading Volume: 379,480

Technical Sentiment Signal: Sell

Current Market Cap: $32.38M

Learn more about SKYE stock on TipRanks’ Stock Analysis page.